[1] Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg, 2019, 154: 209-217. [2] Xu W, Rao Q, An Y, et al. Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function: a double-center study from China. Medicine (Baltimore), 2018, 97:e11800. [3] Cai SH, Lv FF, Zhang YH, et al. Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. BMC Infect Dis, 2014, 14: 85. [4] Jeng KS, Chang CF, Jeng WJ, et al. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit Rev Oncol Hematol, 2015, 94:337-347. [5] Cai S, Cao J, Yu T, et al. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore), 2017, 96:e7021. [6] Romeo R, Petruzziello A, Pecheur EI, et al. Hepatitis delta virus and hepatocellular carcinoma: an update. Epidemiol Infect, 2018, 146:1612-1618. [7] El-Maksoud MA, Habeeb MR, Ghazy HF, et al. Clinicopathological study of occult hepatitis B virus infection in hepatitis C virusassociated hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 2019, 31:716-722. [8] Hassan I, Gane E. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non‐alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. Intern Med J, 2019, 49:1405-1411. [9] Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol, 2019, 54:367-376. [10] Petruzziello A. Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma. Open Virol J, 2018, 12:26-32. [11] Okuda Y, Mizuno S, Shiraishi T, et al. Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus. Biomed Res Int, 2014, 2014: 975380. [12] Oh HJ, Kim TH, Sohn YW, et al. Association of serum alanine aminotransferase and gamma-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J Hepatol, 2011, 17:27-36. [13] Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol, 1999, 31:25-30. [14] Cescon M, Cucchetti A, Grazi GL, et al. Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience. Arch Surg, 2009, 144:906-913. [15] Kondo K, Chijiiwa K, Funagayama M, et al. Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery. J Gastrointest Surg, 2008, 12:468-476. [16] Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology, 2012, 55:1809-1819. [17] Akahoshi H, Taura N, Ichikawa T, et al. Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncol Rep, 2010, 23:1317-1323. |